Overview

Study of VIR-2218 + VIR-3434 in Subjects With Chronic Hepatitis B Virus Infection

Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218+ VIR-3434 and will be assessed for safety, tolerability, and efficacy
Phase:
Phase 2
Details
Lead Sponsor:
Vir Biotechnology, Inc.